Effectiveness of the dexamethasone intravitreal implant for treatment of patients with diabetic macular oedema

Marco Dutra Medeiros, Micol Alkabes, Paolo Nucci

Research output: Contribution to journalArticlepeer-review


Diabetic macular oedema (DMO) is a leading cause of vision loss in the working-age population worldwide. Corticosteroid drugs have been demonstrated to inhibit the expression of both the vascular endothelial growth factor (VEGF) gene and other anti-inflammatory mediators, such as prostaglandins. Triamcinolone, fluocinolone and dexamethasone are the main steroids that have been studied for the treatment of macular oedema. Over the last few years, several studies have suggested an important role for dexamethasone in the management of DMO. The dexamethasone intravitreal implant (DEX implant) (Ozurdex®; Allergan, Inc., Irvine, CA) is a novel approach approved by the US Food and Drug Administration (FDA) and by the EU for the intravitreal treatment of macular oedema after branch or central retinal vein occlusion, and for the treatment of non-infectious uveitis affecting the posterior segment of the eye. We reviewed manuscripts that had investigated the pharmacokinetics, efficacy and safety of the DEX implant regarding DMO treatment.

Original languageEnglish
Pages (from-to)111-116
Number of pages6
JournalEuropean Endocrinology
Issue number2
Publication statusPublished - 2014


  • Corticosteroids
  • Dexamethasone intravitreal implant
  • Implantable drug-delivery system
  • Inflammatory mediators
  • Pathogenesis
  • Refractory diabetic macular oedema

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Endocrine and Autonomic Systems


Dive into the research topics of 'Effectiveness of the dexamethasone intravitreal implant for treatment of patients with diabetic macular oedema'. Together they form a unique fingerprint.

Cite this